0.8906

9.12% -0.0894

Pre-market: .91 0.0194 +2.18%

Coherus Biosciences Inc (CHRS)

Overview News Price History Option Chain Financials Why CHRS Down? Discussions Forecast

Coherus Biosciences Inc stock is traded at $0.8906, with a volume of 2.58M. It is down -9.12% in the last 24 hours and down -23.22% over the past month. Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.

Previous Close:

$0.98

Open:

$0.99

24h Volume:

2.58M

Relative Volume:

1.13

Market Cap:

$103.21M

Revenue:

$257.24M

Net Income/Loss:

$-237.89M

P/E Ratio:

-0.3425

EPS:

-2.6

Net Cash Flow:

$-175.17M

1W Performance:

-10.49%

1M Performance:

-23.22%

6M Performance:

-31.49%

1Y Performance:

-61.28%

1-Day Range:

$0.874

$1.00

1-Week Range:

$0.874

$1.18

52-Week Range:

$0.6603

$2.64

Coherus Biosciences Inc Stock (CHRS) Company Profile

Name

Coherus Biosciences Inc

Sector

Healthcare (1169)

Industry

Biotechnology (679)

Phone

(650) 649-3530

Address

C/O DENNIS M. LANFEAR, REDWOOD CITY, CA

Employee

235

Twitter

@coherus_bio

Next Earnings Date

2025-03-10

Latest SEC Filings

CHRS's Discussions on Twitter

Compare CHRS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CHRS Coherus Biosciences Inc	0.8906	103.21M	257.24M	-237.89M	-175.17M	-2.60
VRTX Vertex Pharmaceuticals Inc	502.92	129.14B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	680.61	74.41B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	581.21	35.31B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	241.75	31.30B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	254.57	27.35B	3.32B	-860.46M	-1.04B	-8.32

Coherus Biosciences Inc Stock (CHRS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-16-24	Downgrade	UBS	Buy → Neutral
Nov-17-23	Initiated	Robert W. Baird	Outperform
Nov-08-23	Downgrade	Maxim Group	Buy → Hold
Jul-24-23	Initiated	Citigroup	Buy
May-01-23	Initiated	Truist	Buy
Mar-28-23	Upgrade	UBS	Neutral → Buy
Jun-14-22	Initiated	UBS	Neutral
Mar-07-22	Downgrade	JP Morgan	Overweight → Neutral
Jul-16-20	Initiated	BofA Securities	Neutral
Apr-17-20	Initiated	SunTrust	Buy
Aug-13-19	Initiated	Mizuho	Buy
Aug-02-19	Reiterated	H.C. Wainwright	Buy
Aug-02-19	Reiterated	Maxim Group	Buy
Jun-11-19	Initiated	Barclays	Overweight
May-07-19	Initiated	H.C. Wainwright	Buy
Aug-28-18	Initiated	H.C. Wainwright	Buy
Mar-09-18	Reiterated	Maxim Group	Buy
Aug-08-17	Reiterated	JP Morgan	Overweight
Jun-13-17	Reiterated	Maxim Group	Buy
May-05-17	Initiated	BMO Capital Markets	Outperform
Oct-19-16	Initiated	Robert W. Baird	Outperform
Sep-07-16	Initiated	Maxim Group	Buy
Jul-27-16	Initiated	Citigroup	Buy
Jan-20-16	Initiated	Credit Suisse	Outperform

View All

Coherus Biosciences Inc Stock (CHRS) Latest News

Mar 13, 2025

Coherus Prepares To Wave Goodbye To Udenyca – And 30% Of Its Staff - Citeline News & Insights

Mar 13, 2025

Coherus BioSciences Shareholders Approve UDENYCA Franchise Sale - Investing.com

Mar 13, 2025

Mar 12, 2025